Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists

Kathy M. Nilles, Stephen H. Caldwell, Steven L. Flamm*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Thrombocytopenia is common in patients with advanced liver disease. These patients frequently require invasive diagnostic or therapeutic procedures in the setting of thrombocytopenia. A common platelet goal before such procedures is ≥50,000/μL, but target levels vary by provider and the procedure. Platelet transfusion has disadvantages, including safety and cost. No other short-term options for ameliorating thrombocytopenia before procedures were available until the thrombopoietin receptor agonists were recently approved. Avatrombopag and lusutrombopag can be used in certain patients with thrombocytopenia due to advanced liver disease undergoing elective invasive procedures; these new agents are highly effective in carefully selected patients, and real world data of safety and efficacy are awaited.

Original languageEnglish (US)
Pages (from-to)1423-1434
Number of pages12
JournalHepatology Communications
Issue number11
StatePublished - Nov 1 2019

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists'. Together they form a unique fingerprint.

Cite this